Biochemistry, Tumor necrosis factor alpha, Chromogranin A, Receptor and Cancer research are his primary areas of study. His Tumor necrosis factor alpha study incorporates themes from Cytokine, Vascular permeability, NGR-hTNF, Cytotoxicity and Pharmacology. Chromogranin A is a primary field of his research addressed under Internal medicine.
His research in Receptor tackles topics such as Molecular biology which are related to areas like Cell surface receptor, Epidermal growth factor and Urokinase. His Cancer research research is multidisciplinary, relying on both Endothelial stem cell, Cytotoxic T cell, Toxicity and Pathology. The study incorporates disciplines such as Blood vessel, Chemotherapy and Neuroblastoma in addition to Pathology.
Angelo Corti mainly investigates Chromogranin A, Internal medicine, Tumor necrosis factor alpha, Cancer research and Biochemistry. The Chromogranin A study combines topics in areas such as Neuroendocrine tumors, Secretory protein, Angiogenesis and Cell biology. He works mostly in the field of Internal medicine, limiting it down to topics relating to Endocrinology and, in certain cases, Endothelial stem cell and Inflammation, as a part of the same area of interest.
His Tumor necrosis factor alpha study combines topics in areas such as Receptor, Melanoma, Cytokine and Pharmacology. His Cancer research study also includes fields such as
Chromogranin A, Internal medicine, Cancer research, Angiogenesis and Endocrinology are his primary areas of study. His Chromogranin A study is associated with Pathology. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Oncology and Cardiology.
His work deals with themes such as Tumor necrosis factor alpha, Cytokine, Immunology, In vitro and Doxorubicin, which intersect with Cancer research. His study in Angiogenesis is interdisciplinary in nature, drawing from both Cancer, Pathogenesis, Pancreastatin, Pathophysiology and Cell biology. His Peptide research integrates issues from Receptor and Integrin.
His primary scientific interests are in Immunology, Internal medicine, Cancer research, Angiogenesis and Tumor necrosis factor alpha. He combines subjects such as Endocrinology and Oncology with his study of Internal medicine. His research in Endocrinology intersects with topics in Cerebrospinal fluid, Chromogranin A and Cell biology.
He has included themes like Biochemistry and Cell adhesion in his Cell biology study. He has researched Angiogenesis in several fields, including Endothelial stem cell, Monoclonal gammopathy of undetermined significance and Protein kinase B. The various areas that Angelo Corti examines in his Tumor necrosis factor alpha study include Cytokine, Tumor microenvironment, Melanoma, Cell therapy and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure
Roberto Ferrari;Tiziana Bachetti;Roberta Confortini;Cristina Opasich.
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.
E Appella;E A Robinson;S J Ullrich;M P Stoppelli.
Journal of Biological Chemistry (1987)
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
M P Stoppelli;A Corti;A Soffientini;G Cassani.
Proceedings of the National Academy of Sciences of the United States of America (1985)
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Flavio Curnis;Angelina Sacchi;Laura Borgna;Fulvio Magni.
Nature Biotechnology (2000)
Autocrine saturation of pro-urokinase receptors on human A431 cells.
M.Patrizia Stoppelli;Carlo Tacchetti;M.Vittoria Cubellis;Angelo Corti.
Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy
Fabio Pastorino;Chiara Brignole;Danilo Marimpietri;Michele Cilli.
Cancer Research (2003)
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Flavio Curnis;Gianluigi Arrigoni;Angelina Sacchi;Lucia Fischetti.
Cancer Research (2002)
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
Flavio Curnis;Angelina Sacchi;Angelo Corti.
Journal of Clinical Investigation (2002)
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Vincent J. Hearing;Lloyd W. Law;Angelo Corti;Ettore Appella.
Cancer Research (1988)
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Fabio Pastorino;Chiara Brignole;Daniela Di Paolo;Bice Nico.
Cancer Research (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: